OTC Pravachol Self-Selection Among Rx Users Needs More Study - NDAC
This article was originally published in The Tan Sheet
Executive Summary
The reasons individuals switch from taking Rx cholesterol-lowering agents to OTC Pravachol (pravastatin) in actual use studies should be the subject of additional examination, FDA advisory committee members suggested to Bristol-Myers Squibb July 14.
You may also be interested in...
Merck, NDAC Chair Neill Cross Paths Again For Oxytrol Switch Meeting
Nonprescription Drugs Advisory Committee member Richard Neill in 2007 praised Merck’s Rx-to-OTC application for Mevacor while voting against the statin switch. On Nov. 9, Merck will try to convince now-chairman Neill and the rest of NDAC that overactive bladder drug Oxytrol can safely be sold OTC.
Merck, NDAC Chair Neill Cross Paths Again For Oxytrol Switch Meeting
Nonprescription Drugs Advisory Committee member Richard Neill in 2007 praised Merck’s Rx-to-OTC application for Mevacor while voting against the statin switch. On Nov. 9, Merck will try to convince now-chairman Neill and the rest of NDAC that overactive bladder drug Oxytrol can safely be sold OTC.
Bristol OTC Pravachol Study Enrollment Does Not Match Indication - FDA
Bristol-Myers Squibb may need to better demonstrate consumers' ability to make self-selection choices based on appropriate cholesterol levels in order to convince FDA that an OTC version of Pravachol is approvable.